Key result
Novel 8-point clinical-CMR score stratifies early post-STEMI major cardiovascular events risk, revealing a ~10-fold difference between risk extremes.
Why the study?
CMR performed early after STEMI can improve MACE risk prediction, prompting the development of a simple clinical-CMR risk score for early risk stratification.
Does a combined clinical-CMR risk score predict MACE in reperfused STEMI patients?
Cohort (n=1,118)
Yes
Does a combined clinical-CMR risk score predict MACE in reperfused STEMI patients?
Answers are grounded in this paper and cite their sources.
A novel 8-point risk score combining clinical and CMR variables effectively stratifies long-term MACE risk in patients early after reperfused STEMI.
BACKGROUND: Cardiac magnetic resonance (CMR) performed early after ST-segment elevation myocardial infarction (STEMI) can improve major adverse cardiac event (MACE) risk prediction. We aimed to create a simple clinical-CMR risk score for early MACE risk stratification in STEMI patients. METHODS: We performed a multicenter prospective registry of reperfused STEMI patients (n = 1118) in whom early (1-week) CMR-derived left ventricular ejection fraction (LVEF), infarct size and microvascular obstruction (MVO) were quantified. MACE was defined as a combined clinical endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (NF-MI) or re-admission for acute decompensated heart failure (HF). RESULTS: During a median follow-up of 5.52 [2.63-7.44] years, 216 first MACE (58 CV deaths, 71 NF-MI and 87 HF) were registered. Mean age was 59.3 ± 12.3 years and most patients (82.8%) were male. Based on the four variables independently associated with MACE, we computed an 8-point risk score: time to reperfusion >4.15 h (1 point), GRACE risk score > 155 (3 points), CMR-LVEF <40% (3 points), and MVO >1.5 segments (1 point). This score permitted MACE risk stratification: MACE per 100 person-years was 1.96 in the low-risk category (0-2 points), 5.44 in the intermediate-risk category (3-5 points), and 19.7 in the high-risk category (6-8 points): p < 0.001 in multivariable Cox survival analysis. CONCLUSIONS: A novel risk score including clinical (time to reperfusion >4.15 h and GRACE risk score > 155) and CMR (LVEF <40% and MVO >1.5 segments) variables allows for simple and straightforward MACE risk stratification early after STEMI. External validation should confirm the applicability of the risk score.
No takes yet. Share an insight, caveat, or question.
Marcos‐Garcés et al. (2021) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=1,118). Clinical-CMR risk score was evaluated on Major adverse cardiac events (cardiovascular death, non-fatal myocardial infarction, or re-admission for acute decompensated heart failure) (p=< 0.001). A novel 8-point clinical-CMR risk score stratified major cardiovascular events risk early after STEMI, with rates of 1.96, 5.44, and 19.7 per 100 person-years in low, intermediate, and high-risk categories.
Synapse has enriched 10 related papers. Consider them for comparative context: